Can GLP-1s cause depression or mood changes?

This question spiked after 2023 case reports and regulatory reviews in Europe; here’s where the evidence settled. The reassuring weight of data: FDA’s preliminary evaluation (January 2024) found no clear causal link between GLP-1s and suicidal thoughts; EMA’s review concluded similarly. Pooled analyses across the STEP program showed psychiatric adverse events comparable to placebo, and several large cohort studies found GLP-1 users had lower rates of depression and suicidal ideation than matched comparators — unsurprising, since weight loss, better sleep (apnea improves), and metabolic improvement generally lift mood. The honest caveats: 1. Trial screening hides tails. Active major depression and suicidality were exclusion criteria, so trials can’t fully characterize what happens in psychiatrically fragile users — which is precisely why decent intake processes screen psychiatric history and why recent psychiatric medication changes are a flag for provider review rather than auto-approval. 2. Plausible individual mechanisms exist. Food is a mood-regulation tool for many people; remove the reward channel pharmacologically and some individuals feel flat or anhedonic even as the average user feels better. Rapid hormonal/metabolic shifts and undereating (fatigue territory) can also masquerade as mood problems. 3. Anecdotes are real even when averages are clean. “The statistics say no signal” and “this particular person feels worse on the drug” can both be true. Practical guidance: baseline matters — flag any depression/anxiety history at intake. On therapy, treat persistent low mood, anhedonia, or any suicidal thinking as report-now events: dose reduction, a pause, or simply ruling out undereating usually clarifies cause quickly. And if you take psychiatric medications, remember slowed gastric emptying can alter absorption timing — worth one interactions conversation.